Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | HSP90B1 | P14625 | 3/20 | 0.35 |
| ▸ | TRAP1 | Q12931 | 3/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | AGXT | P21549 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429889 | 0.85 | AKR1C3 (0.36) | TAAR1 | |
| SCHEMBL18590775 | 0.83 | TAAR1 (0.45) | TAAR1NFE2L2P2RX7ACHECYP1A2 | |
| SCHEMBL13932536 | 0.83 | AMY1A (0.42) | TAAR1NFE2L2P2RX7ACHECYP1A2 | |
| SCHEMBL18354768 | 0.83 | PTGS2 (0.36) | TAAR1NFE2L2ACHECYP1A2 | |
| SCHEMBL10290674 | 0.81 | TAAR1 (0.43) | TAAR1NFE2L2ACHECYP1A2CYP2A6 | |
| SCHEMBL469174 | 0.81 | P2RX7 (0.40) | TAAR1NFE2L2P2RX7ACHECYP1A2 | |
| SCHEMBL17351838 | 0.79 | IDO1 (0.41) | TAAR1NFE2L2P2RX7ACHECYP1A2 | |
| SCHEMBL10889321 | 0.79 | KMT2A (0.43) | TAAR1NFE2L2P2RX7ACHECYP1A2 | |
| SCHEMBL22754160 | 0.79 | TAAR1 (0.38) | TAAR1NFE2L2P2RX7ACHECYP1A2 | |
| SCHEMBL3318682 | 0.79 | TAAR1 (0.38) | TAAR1NFE2L2P2RX7ACHECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9612445-B2 | Lens element | MERCK PATENT GMBH (DE) | 2017-04-04 | — | — | US | disclosed |
| US-20150301344-A1 | LENS ELEMENT | MERCK PATENT GMBH (DE) | 2015-10-22 | — | — | US | disclosed |
| US-9133219-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | Basiliea Pharmaceutica AG | 2015-03-19 | — | — | US | disclosed |
| US-8927542-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2015-01-06 | — | — | US | disclosed |
| US-20140225035-A1 | LIQUID CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | BASILEA PHARMACEUTICA AG (CH) | 2014-08-07 | — | — | US | disclosed |
| US-8716280-B2 | Bicyclic antibiotics | BASILEA PHARMACEUTICA AG (CH) | 2014-05-06 | — | — | US | disclosed |
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2468743-A1 | Nitrogen-containing bicyclic compounds useful as antibacterial agents | Toyama Chemical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-7914859-B2 | Light modulation media, use in particular for electrooptic displays which are operated at a temperature at which the mesogenic modulation media are in an optically isotropic phase, preferably in a blue phase; reduced operating voltage, reduced temperature dependency of operating voltage, reliability | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221348-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | TAAR1 1292/4885NFE2L2 2127/4885P2RX7 1677/4885 |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | TAAR1 3928/4885NFE2L2 2838/4885P2RX7 4837/4885 |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | CRY1, CRY2, IK | TAAR1 239/4885NFE2L2 2055/4885P2RX7 1348/4885 |
| US-20150080373-A1 | NOVEL BICYCLIC ANTIBIOTICS | C1S, XPA, XDH | TAAR1 1292/4885NFE2L2 2127/4885P2RX7 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.